19:44 , Apr 14, 2017 |  BC Week In Review  |  Company News

2-BBB Medicines, TTY Biopharm deal

The companies formed a joint venture in Taiwan to develop and commercialize 2-BBB’s multiple sclerosis candidate 2B3-201. 2-BBB will grant the JV exclusive rights to 2B3-201 and will receive a 33.3% stake in the JV;...
19:46 , Mar 31, 2017 |  BC Week In Review  |  Company News

2-BBB, Oncology Venture deal

2-BBB granted Oncology Venture exclusive, worldwide rights to develop and commercialize 2X-111 (formerly 2B3-101) to treat cancer. The pegylated liposomal doxorubicin conjugated with glutathione has completed a Phase II trial to treat solid tumors, including...
01:30 , Jul 1, 2014 |  BC Extra  |  Financial News

to-BBB raises EUR 10M in series C

Drug delivery company to-BBB technologies B.V. (Leiden, the Netherlands) raised EUR 10 million ($13.7 million) in a series C round from new and existing investors. The company's investors include Aescap Venture; Antea Participaties; Jonghoud International;...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

2B3-101: Phase I/IIa data

Data from 25 patients with brain metastases from solid tumors or recurrent malignant glioma in the Phase I portion of an open-label, dose-escalation, international Phase I/IIa trial showed that 5-60 mg/m 2 doses of IV...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

2B3-101: Phase I/IIa ongoing

to-BBB began the Phase IIa portion of an open-label, dose-escalation, European Phase I/IIa trial to evaluate IV 2B3-101 in about 82 patients with recurrent malignant glioma and patients with brain metastasis from breast cancer, small...
07:00 , May 30, 2013 |  BC Innovations  |  Tools & Techniques

Optimizing transferrin-mediated transcytosis

Researchers at the California Institute of Technology have shown how modulating the transferrin content on gold nanoparticles can optimize their delivery into the brain via the transferrin receptor.1 The group now needs to determine whether...
07:00 , Oct 4, 2012 |  BC Innovations  |  Cover Story

Slipping past P glycoprotein

NIH researchers have shown that sphingosine 1-phosphate receptor agonists such as Novartis AG's Gilenya fingolimod could transiently reduce P glycoprotein-mediated drug efflux and enhance drug delivery to the brain.1 The group at NIH's National Institute...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

2B3-101: Phase I/IIa started

to-BBB began an open-label, dose-escalation, Dutch Phase I/IIa trial to evaluate 2B3-101 in about 40 patients. The trial includes an extension phase in 10 patients with brain metastases of breast cancer. to-BBB technologies B.V., Leiden,...
07:00 , Nov 4, 2010 |  BC Innovations  |  Cover Story

LAMbasting brain cancer

Approved therapies to treat brain cancer are not entirely tumor cell-specific and thus can have severe dose-limiting toxicities that decrease their effectiveness. A team of U.S. and German researchers thinks it has overcome this problem...
07:00 , Jun 21, 2010 |  BC Week In Review  |  Clinical News

2B3-101 regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation to to-BBB's 2B3-101 to treat glioma. The liposomal doxorubicin formulation, which is conjugated with glutathione to enhance delivery across the blood-brain barrier, is expected...